The study on the preventive effect of irsogladine for gastric bleeding risk of antithrombotic drugs after ESD -multicenter randomized controlled study of irsogladine + PPI versus PPI alone
Phase 4
- Conditions
- gastric tumor(early gastric cancer, gastric adenoma)
- Registration Number
- JPRN-UMIN000012434
- Lead Sponsor
- Osaka Medical College
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
Not provided
Exclusion Criteria
1)Subjects with hematemesis, melena or anemia lack of hemoglobin 2 g/dL or more during the observation period 2)Subjects with significant hepatic disease, renal disease, heart disease or respiratory disease 3)Subjects with a history of gastrointestinal surgery other than appendectomy 4)Subjects orally taking or planning to orally take drug other than rabeprazole or irsogladine 5)Pregnancy or lactation 6)Subjects whom otherwise the investigator determined ineligible as the subject
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method